Determination of ecabet in human plasma by high-performance liquid chromatography-tandem mass spectrometry

被引:10
作者
Zhang, Dan [1 ]
Du, Xiaolin [1 ]
Liu, Mingyuan [1 ]
Li, Hao [1 ]
Jiang, Yao [1 ]
Zhao, Limei [2 ]
Gu, Jingkai [1 ]
机构
[1] Jilin Univ, Res Ctr Drug Metab, Changchun 130023, Peoples R China
[2] Chinese Med Univ, Clin Hosp 2, Shenyang 110004, Peoples R China
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2008年 / 863卷 / 02期
关键词
ecabet; LC-MS/MS;
D O I
10.1016/j.jchromb.2008.01.013
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
This paper describes a simple, robust and cost-effective assay for the determination of ecabet in human plasma. After a simple step of protein precipitation using methanol, plasma samples were analyzed by reverse phase high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry (HPLC-ESI-MS/MS) with valsartan as the internal standard (I.S.). Ecabet and the I.S. valsartan were separated on a Venusil NIP C18 analytical column using methanol-10mM ammonium acetate (75:25, v/v, pH 3.0) as mobile phase at a flow rate of 1.0 mL/min. Ecabet and I.S. were eluted at 0.91 and 0.92 min, respectively, ionized in negative mode, and then detected by multiple reaction monitoring (MRM) essay. The MRM transitions of m/z 379.1 -> m/z 277.1 and m/z 434.3 -> m/z 350.1 were used to quantify ecabet and I.S., respectively. The assay was linear over the concentration range of 10-6000 ng/mL and was successfully applied to a pharmacokinetic study in healthy volunteers. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:223 / 228
页数:6
相关论文
共 32 条
[1]  
Ackermann Bradley L., 2002, Current Topics in Medicinal Chemistry, V2, P53, DOI 10.2174/1568026023394605
[2]   Efficacy of ecabet sodium for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen [J].
Adachi, K ;
Ishihara, S ;
Hashimoto, T ;
Hirakawa, K ;
Ishimura, N ;
Niigaki, M ;
Kaji, T ;
Kawamura, A ;
Sato, H ;
Fujishiro, H ;
Hattori, S ;
Watanabe, M ;
Kinoshita, Y .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (08) :1187-1191
[3]  
FURUTA T, 1998, GASTROENTEROLOGY S, V114, pA127
[4]   Combined effect of rebamipide and ecabet sodium on Helicobacter pylori adhesion to gastric epithelial cells [J].
Hayashi, S ;
Sugiyama, T ;
Yokota, K ;
Isogai, H ;
Isogai, E ;
Shimomura, H ;
Oguma, K ;
Asaka, N ;
Hirai, Y .
MICROBIOLOGY AND IMMUNOLOGY, 2000, 44 (07) :557-562
[5]   Effects of ecabet sodium, a novel gastroprotective agent, on mucin metabolism in rat gastric mucosa [J].
Ichikawa, T ;
Ishihara, K ;
Hayashida, H ;
Hiruma, H ;
Saigenji, K ;
Hotta, K .
DIGESTIVE DISEASES AND SCIENCES, 2000, 45 (03) :606-613
[6]   Efficacy of ecabet sodium enema on steroid resistant or steroid dependent ulcerative colitis [J].
Iizuka, M. ;
Itou, H. ;
Konno, S. ;
Shirasaka, T. ;
Horie, Y. ;
Shindo, K. ;
Watanabe, S. .
GUT, 2006, 55 (10) :1523-1523
[7]   Ecabet sodium, a locally acting antiulcer drug, inhibits urease activity of Helicobacter pylori [J].
Ito, Y ;
Shibata, K ;
Hongo, A ;
Kinoshita, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 345 (02) :193-198
[8]   EFFECTS OF THE NEW ANTIULCER DRUG ECABET SODIUM (TA-2711) ON PEPSIN ACTIVITY .1. INACTIVATION OF ENZYME PROTEIN [J].
ITO, Y ;
NAKAMURA, S ;
ONODA, Y ;
SUGAWARA, Y ;
TAKAITI, O .
JAPANESE JOURNAL OF PHARMACOLOGY, 1993, 62 (02) :169-174
[9]   METABOLIC-FATE OF A NEW ANTIULCER DRUG (+)-(1R,4AS,10AR)-1,2,3,4,4A,9,10,10A-OCTAHYDRO-1,4A-DIMETHYL-7-(1-METHYLETHYL)-6-SULFO-1-PHENANTHRENECARBOXYLIC ACID 6-SODIUM SALT PENTAHYDRATE (TA-2711) .2. DISTRIBUTION IN THE RAT STOMACH [J].
ITO, Y ;
SUGAWARA, Y ;
TAKAITI, O ;
NAKAMURA, S .
JOURNAL OF PHARMACOBIO-DYNAMICS, 1991, 14 (09) :547-554
[10]   METABOLIC-FATE OF A NEW ANTIULCER DRUG (+)-(1R, 4AS, 10AR)-1,2,3,4,4A,9,10,10A-OCTAHYDRO-1,4A-DIMETHYL-7-(1-METHYLETHYL)-6-SULFO-1-PHENANTHRENECARBOXYLIC ACID 6-SODIUM SALT PENTAHYDRATE (TA-2711) .1. DISPOSITION, METABOLISM AND PROTEIN-BINDING IN RATS AND DOGS [J].
ITO, Y ;
FUKUSHIMA, T ;
SUGAWARA, Y ;
TAKAITI, O ;
NAKAMURA, S .
JOURNAL OF PHARMACOBIO-DYNAMICS, 1991, 14 (09) :533-546